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Summary
Objectives:	There	is	no	licensed,	dose-	appropriate	formulation	of	hydrocortisone	for	
children	with	adrenal	insufficiency	(AI)	and	patients	rely	on	compounded	adult	medica-
tion.	The	aim	of	this	study	was	to	evaluate	the	absorption,	palatability	and	safety	of	
Infacort®,	 an	 immediate-	release,	 granule	 formulation	 of	 hydrocortisone	 with	 taste	
masking.
Study design:	Single	site	with	satellites	attended	by	a	“flying”	doctor	from	investigator	
site.	Open-	label,	single-	dose	study	in	three	consecutive	child	cohorts	(n	=	24)	with	AI;	
Cohort	 1,	 children	 aged	 2	 to	 <6	years	 (n	=	12);	 Cohort	 2,	 infants	 aged	 28	days	 to	
<2	years	(n	=	6);	Cohort	3,	neonates	aged	1	to	<28	days	(n	=	6).	
Methods:	Fasted	children	were	given	a	single	dose	of	Infacort®	as	dry	granules	admin-
istered	directly	from	a	capsule	or	spoon	followed	by	a	drink.	The	primary	end-	point	
was	 the	maximum	 serum	 cortisol	 concentration	 up	 to	 240	minutes	 after	 Infacort® 
	administration.	Secondary	end-	points	were	palatability	and	adverse	events	(AEs).
Results:	 All	 children	 showed	 an	 increase	 in	 cortisol	 above	 baseline	 after	 Infacort® 
(P <	.0001),	 with	 geometric	 mean	±	SD	 cortisol	 concentration	 at	 60	minutes	 of	
575.8	±	299.5	nmol	L−1.	There	was	no	failure	in	administration	of	Infacort®,	and	95.5%	of	
parents/carers	preferred	Infacort®	to	their	child’s	current	medication.	In	7	children	who	
completed	the	palatability	questionnaire,	80%	of	responses	were	very	good	or	neutral,	
and	20%	were	adverse.	No	serious	or	severe	treatment-	emergent	AEs	were	reported.
Conclusions:	 Infacort®	 is	well	tolerated,	easy	to	administer	to	neonates,	 infants	and	
children	and	shows	good	absorption,	with	cortisol	levels	at	60	minutes	after	adminis-
tration	similar	to	physiological	cortisol	levels	in	healthy	children.
K E Y W O R D S
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granules
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1  | INTRODUCTION
The	commonest	cause	of	adrenal	insufficiency	(AI)	in	childhood	is	con-
genital	adrenal	hyperplasia	(CAH),	and	children	require	glucocorticoid	
replacement	 from	 birth	 to	 end	 of	 life.1	 The	 recommended	 replace-
ment	 therapy	 is	 hydrocortisone,2,3	 but	 there	 are	 no	 licensed	 dose-	
appropriate	 formulations	 of	 hydrocortisone	 for	 children.	 Children	
rely	either	on	parents	crushing	 tablets	or	pharmacists	 compounding	
adult	medication.	However,	 compounding	 is	 regulated	by	 less	 strin-
gent	criteria	than	those	used	for	licensed	drugs	as	compounded	drugs	
are	neither	approved	by	the	European	Medicines	Agency	 (EMA)	nor	
Food	and	Drug	Administration	(FDA)	nor	required	to	demonstrate	ef-
ficacy.4	There	 is	 also	 exemption	 from	Good	Manufacturing	 Practice	
(GMP)	requirement	in	manufacture	for	compounded	medicines	which	
increases	the	risks	of	 inaccurate	dosing.4	A	recent	assessment	of	56	
batches	of	hydrocortisone	capsules	prepared	for	children	in	Germany	
revealed	that	25%	did	not	meet	the	European	Pharmacopoeia	accep-
tance	 criteria	 for	precision	of	mass	 and/or	 content,5	 and	difficulties	
with	 crushing	 hydrocortisone	 tablets	 have	 been	 highlighted	 in	 the	
UK.6	Furthermore,	because	hydrocortisone	is	bitter,	powders	and	sus-
pensions	created	by	compounding	pharmacists	are	often	sweetened	
with	sugar	to	improve	palatability	(http://www.sickkids.ca/Pharmacy/
Compounding-Service/),	which	is	contrary	to	current	paediatric	guid-
ance	(Guideline	on	pharmaceutical	development	of	medicines	for	pae-
diatric	use	(1	August	2013	EMA/CHMP/QWP/805880/2012	Rev.	2,	
Committee	for	Medicinal	Products	for	Human	Use	[CHMP],	Paediatric	
Committee	[PDCO]).
Hydrocortisone	as	 replacement	 therapy	 in	AI	has	a	narrow	ther-
apeutic	 index,	and	patients	with	CAH	have	poor	health	outcomes	in	
adulthood,	which	are	 in	part	 related	 to	 treatment	 in	 childhood.7,8	A	
recent	 survey	of	paediatric	 endocrinologists	 across	16	 countries	 re-
vealed	wide	heterogeneity	in	the	hydrocortisone	formulations	used	to	
treat	 children,	with	60%	using	divided	 licensed	 tablets.9	The	 lowest	
dose	available	for	hydrocortisone	in	the	USA	is	a	5	mg	tablet	and,	in	
Europe,	10	mg,	but	the	average	dose	used	in	paediatrics	is	2	mg	with	
doses	as	low	as	0.5	mg	required	for	neonates	and	infants.9	A	hydrocor-
tisone	suspension	was	available	in	the	USA	but	is	no	longer	marketed	
as	it	was	not	bioequivalent	to	tablets.10	There	is	therefore	an	unmet	
need	to	develop	a	 licensed	paediatric	 formulation	of	hydrocortisone	
specifically	designed	for	the	treatment	of	children	with	AI	and	CAH.
Paediatric	patients	have	specific	requirements	for	drug	formulation	
that	include	an	appropriate	dosing	route,	improved	palatability,	ease	of	
administration	for	caregivers,	dosing	flexibility	and	stability.	Infacort® 
(Diurnal	Ltd,	Cardiff,	UK)	is	a	new,	immediate-	release,	multiparticulate	
granule	formulation	of	hydrocortisone	with	taste-	masking	designed	to	
be	administered	either	as	dry	granules	or	mixed	with	a	small	amount	
of	food,	directly	into	the	mouths	of	neonates,	infants	and	children	fol-
lowed	by	a	drink	(Figure	1).	Infacort®	granules	are	less	than	2	mm	in	
diameter	allowing	for	dosing	safely	in	neonates	(Guidance	for	Industry	
Size	of	Beads	in	Drug	Products	Labelled	for	Sprinkle	FDA	May	2012).	
A	 Phase	 1	 study	 of	 Infacort®	 demonstrated	 good	 tolerability	 and	
palatability	and	bioequivalence	 to	 licensed	hydrocortisone	 tablets	 in	
healthy	volunteers.9	Undertaking	clinical	trials	in	neonates,	infants	and	
children	is	challenging	for	practical	and	ethical	reasons	and	for	this	rea-
son	off-	label	use	accounts	for	up	to	60%	of	medicines	administered	to	
children	in	Europe	and	the	United	States.11,12	To	date,	there	have	only	
been	two	medications	licensed	in	Europe	through	the	EMA	Paediatric	
Use	Marketing	Authorisation	(PUMA)	route.	To	support	a	PUMA,	and	
as	part	of	a	 larger	European	Commission	funded	project	 to	 improve	
therapy	for	children	with	adrenal	insufficiency	(http://www.tain-proj-
ect.org/),	we	undertook	a	study	in	neonates,	infants	and	children	aged	
<6	years	with	AI,	designed	to	evaluate	the	absorption,	palatability	and	
safety	of	Infacort®.
2  | SUBJECTS AND METHODS
2.1 | Trial design
This	was	a	Phase	3,	open-	label,	single-	dose	study	conducted	at	a	sin-
gle	 centre;	Charité-	Universitätsmedizin,	 Berlin,	Germany.	 The	 study	
F IGURE  1  Illustration	of	Infacort® 
formulation	and	its	administration
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enrolled	 subjects	 into	 three	 consecutive	 cohorts:	 Cohort	 1,	 chil-
dren	(aged	2	to	<6	years,	n	=	12);	Cohort	2,	infants	(aged	28	days	to	
<2	years,	n	=	6);	and	Cohort	3,	neonates	(aged	1	to	<28	days,	n	=	6).	
Neonatal	 participants	 were	 also	 recruited	 at	 remote	 sites	 but	 had	
their	care	transferred	to	the	central	site	for	the	duration	of	the	study	
through	 a	 “flying”	 doctor	 concept	whereby	 central-	site	 staff	 visited	
remote	sites	to	perform	study	assessments.	All	participants	required	
hydrocortisone	replacement	therapy	for	AI	due	to	CAH	or	hypopitui-
tarism.	Cohorts	were	studied	sequentially	such	that	when	no	safety	
issues	 were	 found	 in	 Cohort	 1	 then	 Cohort	 2	 was	 recruited.	 Data	
were	reviewed	by	the	Independent	Data	Monitoring	Committee	and	
BfArM	(The	Federal	Institute	for	Drugs	and	Medical	Devices)	before	
neonates	were	enrolled	(Cohort	3).	The	trial	comprised	three	hospital	
visits:	eligibility	screening	(Visit	1,	between	Day	−28	and	−1),	dosing	
(Visit	2,	Day	1)	and	a	follow-	up	visit	(Visit	3,	on	Day	2,	3	or	4)—and	a	
follow-	up	phone	call	(Visit	4,	between	Day	8	and	11).
2.2 | Ethics
Parents/carers	signed	an	Informed	Consent	Form.	The	trial	protocol	
complied	with	 the	 ethical	 principles	 of	 the	Declaration	 of	 Helsinki,	
International	 Council	 for	 Harmonisation	 (ICH)	 and	 Good	 Clinical	
Practice	 (GCP),	 met	 with	 German	 regulatory	 authority	 (BfArM)	
	requirements	and	was	approved	by	the	relevant	 independent	ethics	
committee	(Ethics	committee	of	Berlin,	No.	14/0517-	EK	12).
Clinical	trial	registration	number:	EudraCT	No.	2014-	002265-	30;	
ClinicalTrials.gov	NCT02720952.
2.3 | Study population
Comprised	 adequately	 hydrated	 and	 nourished	 children	 (male	 or	
female)	 aged	 <6	years	 diagnosed	 with	 AI	 (confirmed	 by	 an	 inap-
propriately	low	cortisol	level)	who	were	currently	receiving	hydro-
cortisone	with	or	without	fludrocortisone.	Children	were	excluded	
from	the	study	 if	 they:	were	experiencing	a	current	adrenal	crisis;	
had	 clinical	 signs	 of	 acute	 infection	 or	 fever	 on	Day	 1;	were	 un-
able	to	take	oral	medications;	were	receiving	concomitant	therapy	
(other	 than	 for	AI,	 vitamin	D,	 fluoride,	 thyroxine	and	growth	hor-
mone,	which	were	 permitted);	 had	 a	 parent/carer	who	 could	 not	
understand	or	give	written	consent	or	were	unwilling	to	consent	to	
the	saving	and	propagation	of	pseudonymized	medical	data	in	this	
study	(Table	1).
2.4 | Treatment
Infacort®	was	supplied	as	capsules	containing	0.5,	1.0,	2.0	&	5.0	mg	
doses	 of	 immediate-	release	 multiparticulate	 granules	 (Figure	1).	
All	 participants	were	given	a	 single	dose	of	 Infacort®	 at	 study	Visit	
2	 that	was	equivalent	 to	 their	 routine	hydrocortisone	dose	 (Cohort	 
1:	4.01	±	0.8	mg/m2	body	surface	area	(BSA),	Cohort	2:	4.98	±	0.8	mg/m2 
BSA,	 Cohort	 3:	 8.43	±	2.4	mg/m2	 BSA;	 for	 further	 information	 on	
dosing	see	Table	S1);	the	dose	was	poured	directly	onto	the	subject’s	
tongue	or	on	a	spoon	and	administered	as	dry	granules	followed	by	
a	drink	of	water	or	breastmilk	in	newborns.	As	food	has	been	noted	
to	 delay	 hydrocortisone	 absorption	 and	 prolong	 response,13	 dosing	
took	place	 at	 least	 2	hours	 after	 food	 in	 children	 aged	≥1	year	 and	
45	minutes	 in	children	aged	<1	year	and	at	 least	8	hours	after	 their	
last	dose	of	hydrocortisone.	Participants	did	not	eat	after	 Infacort® 
administration	 for	60	minutes	 in	 children	 aged	≥1	year	 and	30	min-
utes	 in	 children	 aged	 <1	year.	 Other	 than	 replacing	 their	 standard	
morning	hydrocortisone	dose	with	Infacort®	on	the	day	of	administra-
tion,	subjects	continued	to	receive	their	standard	AI	treatment,	includ-
ing	fludrocortisone.	Subjects	continued	their	standard	hydrocortisone	
treatment	8	hours	after	Infacort®	administration.
2.5 | End- points
The	 primary	 end-	point	 of	 this	 study	was	maximum	 serum	 cortisol	
concentration	 up	 to	 240	minutes	 after	 Infacort®	 administration	
using	samples	taken	at	0,	60	and	240	minutes	postdose.	Secondary	
end-	points	included	palatability	of	Infacort®,	AEs	and	vital	signs	re-
corded	during	 the	 study.	Clinical	 or	 laboratory	 events	 related	 to	 a	
lack	of	absorption	of	hydrocortisone	from	Infacort®	were	considered	
as	demonstrating	a	lack	of	efficacy	and	were	therefore	not	recorded	
as	AEs.
2.6 | Assessments
During	Visit	2,	all	study	cohorts	had	blood	samples	taken	at	base-
line,	60	and	240	minutes	for	serum	cortisol	after	Infacort® admin-
istration.	The	60-	minute	cortisol	sample	was	divided	into	aliquots	
with	one	sample	measured	immediately	for	safety	using	the	local	
immunoassay	 method	 (Elecsys	 Cortisol,	 Roche	 Diagnostics).	 In	
the	protocol,	it	was	stated	that	if	the	Investigator	judged	the	par-
ticipant	 needed	 supplementary	 hydrocortisone	 after	 Infacort® 
administration	and/or	 the	60-	minute	 safety	 cortisol	 assessment	
result	was	<100	nmol	L−1,	an	additional	cortisol	sample	would	be	
taken,	 and	 emergency	 hydrocortisone	 would	 be	 administered;	
however,	 this	 action	was	not	 taken	during	 the	 trial.	 Serum	cor-
tisol	 levels	were	measured	using	previously	 reported,	validated,	
liquid	chromatography-	mass	spectrometry	at	the	central	 labora-
tory	 (Simbec	 Research	 Ltd,	 Merthyr	 Tydfil,	 UK)9;	 only	 baseline	
and	 the	 60-	minute	 safety	 cortisol	 samples	 were	 additionally	
measured	 at	 local	 hospital	 laboratories.	 AEs	 were	 assessed	 at	
Visits	2,	3	and	4	using	nondirect	questioning	following	instruction	
to	the	parent/carer	to	observe	the	child	carefully	after	Infacort® 
administration.	Physical	examinations	and	vital	sign	assessments	
(blood	pressure,	pulse	and	body	temperature)	were	performed	at	
Visits	1,	2	and	3.	In	the	absence	of	a	validated	palatability	ques-
tionnaire,	the	study	sponsor	(Diurnal	Ltd,	Cardiff,	UK)	developed	
a	questionnaire	in	collaboration	with	the	CAH	UK	Support	Group	
(Leeds,	UK).	 Parents/carers	were	 queried	 about	 the	 palatability	
of	Infacort®,	after	administration,	using	a	5-	item	Likert	scale	and	
children	in	Cohort	1	who	were	able	to	understand	the	questions	
were	queried	about	the	palatability	of	Infacort®	after	administra-
tion	using	an	adjusted	5-	item	Likert	questionnaire	(see	Table	S1).
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2.7 | Statistical methods
Pharmacokinetic	 (PK)	 data	 from	 two	Phase	 1	 studies	 (ClinicalTrials.
gov	Reference	No.	NCT02777268	&	NCT01960530)	of	Infacort® in 
healthy	adult	volunteers9	were	used	to	derive	and	minimize	the	popu-
lation	size	 in	 the	current	 study	and,	as	a	 result,	 this	 study	aimed	 to	
enrol	24	subjects	as	this	provided	>90%	power	(alpha	1%)	to	demon-
strate	that	cortisol	levels	were	higher	than	baseline	after	administra-
tion	of	 Infacort®.	The	safety	population	comprised	all	 subjects	who	
received	one	complete	or	partial	dose	of	 Infacort®.	The	PK	popula-
tion	included	all	subjects	in	the	safety	population	for	whom	there	was	
an	adequate	set	of	data	to	derive	the	maximum	serum	concentration	
(Cmax)	of	cortisol	without	any	major	PK-	related	protocol	violations	(eg	
incomplete	Infacort®	intake	or	vomiting).	All	cortisol	absorption	analy-
ses	(primary	and	secondary)	were	performed	based	on	the	PK	popula-
tion,	using	data	determined	by	the	central	laboratory.	Safety	analyses	
were	conducted	in	the	safety	population;	no	formal	statistical	testing	
was	performed	for	safety	end-	points.	All	variables	were	presented	by	
cohort	and	overall.	The	hypothesis	that	cortisol	Cmax	up	to	240	min-
utes	 after	 Infacort®	 administration	was	higher	 than	at	baseline	was	
tested	using	a	sign	test	with	a	significance	level	of	1%.	This	statistical	
analysis	was	repeated	based	on	cortisol	levels	at	60	and	240	minutes	
after	Infacort®	administration.	A	95%	confidence	interval	(CI)	for	the	
ratio	 of	maximum	 cortisol	 levels	 versus	 baseline	 cortisol	 levels	was	
presented	using	a	paired	t	test	for	log	concentration	data.	Confidence	
limits	based	on	the	 log	data	were	back-	transformed	to	provide	a	CI	
for	the	ratio.	The	same	approach	was	used	to	calculate	95%	CIs	for	
the	ratio	of	cortisol	levels	at	60	and	240	minutes	after	Infacort® ad-
ministration	 vs	baseline.	Cortisol	 levels	were	 also	 categorized	using	
the	 following	 groups:	 <50	nmol	L−1;	 ≥50	 and	 <100	nmol	L−1;	 ≥100	
and	<150	nmol	L−1;	and	≥150	nmol	L−1.	No	adjustments	for	covariates	
were	performed	in	this	study.
3  | RESULTS
3.1 | Study population characteristics
Demographic	and	other	baseline	characteristics	for	the	study	subjects	
are	shown	in	Table	1.	In	total,	24	children	were	enrolled	in	the	study:	
Cohort	1,	12	children	with	CAH,	5	girls	and	7	boys;	Cohort	2,	5	infants	
TABLE  1 Demographic	and	other	baseline	characteristics.	Cohort	1:	children	aged	2	to	<6	years,	Cohort	2:	children	aged	28	days	to	
<2	years.	Cohort	3:	neonates	aged	1	to	<28	days
Characteristic Cohort 1 (n = 12) Cohort 2 (n = 6) Cohort 3 (n = 6) Overall (n = 24)
Mean	(SD)	age,	weeks 171.7	(49.2) 63.9	(30.8) 3.2	(0.5) 102.6	(82.6)
Median	(range)	age,	weeks 171.0	(106.3,	244.0) 70.9	(17.7,	94.9) 3.3	(2.3,	3.7) 100.6	(2.3,	244)
Male,	% 7	(58.3) 4	(66.7) 2	(33.3) 13	(54.2)
Ethnic	origin
White,	n	(%) 12	(100) 6	(100) 6	(100) 24	(100)
Mean	(SD)	body	mass	index	(kg/m2) 17.4	(1.7) 17.7	(1.5) 12.7	(1.8) 16.3	(2.6)
Median	(ranges)	body	mass	index	(kg/m²) 17.4	(14.6,	20.6) 17.3	(16.4,	20.5) 12.3	(11.0,	15.1) 16.6	(11.0,	20.6)
Mean	body	mass	index	SDS	(SD) 1.02	(1.0) 0.71	(0.9) a
Median	(ranges)	body	mass	index	SDS 0.96	(−0.7,	2.1) −0.31	(−1.3,	2.0) a 0.06	(−1.3,	2.1)
Mean	(SD)	body	surface	area	(m2) 0.64	(0.08) 0.44	(0.08) 0.22	(0.03) 0.49	(0.19)
Median	(ranges)	body	surface	area	(m²) 0.64	(0.5,	0.8) 0.49	(0.3,	0.5) 0.22	(0.2,	0.3) 0.51	(0.2,	0.8)
Concomitant	medications
n	(%) 12	(100) 6	(100) 6	(100) 24	(100)
Vitamins 0 1	(16.7) 4	(66.7) 5	(20.8)
Fludrocortisone 12	(100) 5	(83.3) 6	(100) 23	(95.8)
Thyroxine 0 1	(16.7) 0 1	(4.2)
Concurrent	conditions
n	(%)
Virilismb 1	(8.3) 0 4	(66.7) 5	(20.8)
Hypothyroidism 0 1	(16.7) 0 1	(4.2)
Rhinitis 0 1	(16.7) 0 1	(4.2)
Skin	infection 1	(8.3) 0 0 1	(4.2)
Renal	hypoplasia 0 0 1	(16.7) 1	(4.2)
Atopic	dermatitis 1	(8.3) 0 0 1	(4.2)
aBMI-	SDS	not	calculable	due	to	missing	reference	data	in	newborns.
bVirilisation	of	the	female	genitalia	according	Prader	stage	II-	IV.
     |  5NEUMANN Et Al.
with	CAH,	1	child	with	hypopituitarism,	2	girls,	4	boys;	Cohort	3,	6	neo-
nates	with	CAH,	4	girls,	2	boys.	One	neonate	was	from	the	Charité	site,	
and	5	were	from	satellite	sites	treated	by	a	“flying”	investigator	team.	
Median	 participant	 age	 was	 3	years	 and	 3	months	 and	 54.2%	 were	
male;	all	subjects	were	white.	All	subjects	were	successfully	dosed.
3.2 | Hydrocortisone absorption
The	 primary	 end-	point	 of	 the	 study	 was	 met	 as	 shown	 in	 Figure	2.	
Increases	 from	 baseline	 in	 cortisol	 Cmax	 up	 to	 240	minutes	 after	
Infacort®	 administration	were	statistically	 significant	 for	 the	combined	
study	cohorts	 (P <	.0001).	A	relevant	 increase	from	baseline	 in	cortisol	
Cmax	was	 observed	 in	 all	 patients	 from	 all	 three	 cohorts.	 The	 cortisol	
Cmax	was	observed	at	60	minutes	 in	each	cohort	 and	overall.	The	ab-
solute	geometric	±SD	(standard	deviation)	mean	cortisol	concentration	
at	Cmax	was	575.8	±	299.5	nmol	L
−1	 for	 the	overall	population	 (Cohort	
1:	 547.1	±	82.9	nmol	L−1;	 Cohort	 2:	 450.1	±	88.9	nmol	L−1;	 Cohort	 3:	
815.7	±	474.9	nmol	L−1).	 A	 summary	 of	 the	 primary	 efficacy	 analysis	
across	 all	 study	 cohorts	 and	 the	 geometric	mean	 serum	 cortisol	 con-
centrations	 at	 baseline	 and	 after	 Infacort®	 administration	 is	 shown	 in	
Table	2.	 Results	 of	 the	 primary	 analysis	were	 confirmed	 in	 a	 second-
ary	analysis	using	the	paired	t	 test.	The	ratios	of	geometric	means	for	
the	comparison	of	cortisol	concentration	at	Cmax	(60	minutes)/baseline	
were	 statistically	 significant	 overall	 (2535.0	 [95%	CI	 1792.4,	 3585.3];	
P	<	.0001)	and	for	each	cohort	 (P <	.0001,	P =	.0007	and	P	<	.0001	for	
Cohorts	 1,	 2	 and	 3,	 respectively).	 The	 ratios	 of	 geometric	means	 for	
cortisol	concentrations	at	240	min/baseline	were	also	significant	over-
all	(247.1	[95%	CI	161.6,	377.7];	P	=	.0002)	and	in	Cohort	1	(P <	.0001)	
but	were	not	significant	for	Cohorts	2	and	3	(P	=	.4654	and	P	=	.0905,	
respectively).	At	60	minutes	(Cmax),	100%	of	the	participants	had	cortisol	
concentrations	≥150	nmol	L−1	(91.7%	of	subjects	had	a	cortisol	concen-
tration	<50	nmol	L−1	 at	baseline).	By	240	minutes	 after	 Infacort®	 dos-
ing,	41.7%	of	participants	had	cortisol	concentrations	<50	nmol	L−1,	and	
8.7%	of	participants	had	cortisol	concentrations	≥150	nmol	L−1.
3.3 | Palatability
Infacort®	 was	 positively	 assessed	 in	 terms	 of	 palatability.	 Among	
parents	and	carers	asked	about	their	child’s	experience	of	taking	the	
medication	 (n	=	23),	 82.6%	 agreed/strongly	 agreed	 that	 their	 child	
found	swallowing	Infacort®	easy;	65.2%	agreed/strongly	agreed	that	
their	child	showed	a	positive	reaction	after	Infacort®	administration;	
95.5%	would	be	happy	to	give	their	child	Infacort®	in	the	future;	and	
95.5%	said	that	they	would	prefer	Infacort®	for	their	child’s	treatment	
over	their	usual	hydrocortisone	formulation.	Seven	of	the	12	children	
in	Cohort	1	 (age	range	2.6-	4.7	years)	 responded	to	an	adjusted	pal-
atability	 questionnaire.	 Responses	 were	 again	 generally	 positive	 or	
neutral	(Table	3),	with	≥50%	subjects	reporting	that	the	taste,	feel	in	
F IGURE  2 Cortisol	levels	following	InfacortR	administration	in	all	subjects	(A),	Cohort	1:	children	aged	2	to	<6	years	(B),	Cohort	2:	infants	
aged	1	month-	<2	years	(C)	and	Cohort	3:	neonates	aged	1	to	≤28	days	(D).	InfacortR	produced	a	clinically	significant	rise	in	cortisol	in	all	three	
cohorts
(A) (B)
(C) (D)
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mouth	and	ease	of	 swallowing	were	very	good	and	 that	 they	were	
likely	to	take	the	medicine	again.	 In	addition,	4	of	7	subjects	stated	
that	the	smell	of	Infacort®	was	neutral.
3.4 | Safety
There	was	 no	 significant	 spillage	 of	 granules,	 and	 all	 subjects	were	
successfully	dosed	(Table	4).	Twelve	treatment-	emergent	AEs	(TEAEs)	
were	reported	by	8	children:	33.3%	of	participants	overall;	33.3%	of	
participants	in	each	cohort.	No	serious	or	severe	TEAEs	were	reported,	
and	no	TEAEs	were	adjudicated	to	have	resulted	from	treatment	with	
Infacort®.	The	most	common	TEAEs	reported	were	diarrhoea,	vomit-
ing	and	rash.	No	AI	events	were	observed.	No	changes	from	baseline	
in	vital	signs	were	reported	as	TEAEs.
4  | DISCUSSION
This	study	examined	adrenal	replacement	therapy	in	a	preschool	pop-
ulation	using	a	formulation	specifically	designed	for	neonates,	infants	
and	children.	Infacort®	given	as	dry	granules	to	neonates	and	children	
up	 to	 6	years	with	 AI	was	well	 tolerated	 and	 provided	 appropriate	
exposure	to	cortisol.	The	mean	cortisol	level	in	the	children	after	tak-
ing	their	standard	hydrocortisone	dose	as	Infacort®	was	626	nmol	L−1,	
very	 similar	 to	 the	 mean	 peak	 concentrations	 of	 cortisol	 seen	 in	
healthy	paediatric	subjects	in	the	early	morning	of	691	nmol	L−1.14	All	
the	children	had	a	cortisol	concentration	at	60	mins	≥150	nmol	L−1,	
which	is	equivalent	to	the	median	daily	cortisol	 level	in	adults15 and 
physiological	cortisol	levels	in	adult	and	paediatric	patients	are	simi-
lar.14	All	of	the	children	who	completed	the	children’s	questionnaire	
felt	Infacort®	tasted	good	or	not	bad	and	parents	and	carers	felt	it	was	
better	than	their	child’s	current	medication.
There	was	no	comparator	hydrocortisone	preparation	in	this	study	
as	there	is	no	licensed	dose-	appropriate	preparation	of	hydrocortisone,	
and	there	is	neither	a	standard	method	for	compounding	hydrocorti-
sone	nor	for	administering	compounded	hydrocortisone.	Furthermore,	
the	 results	of	 such	a	 study	would	not	be	possible	 to	extrapolate	 to	
another	compounding	pharmacy.	However,	Infacort®	given	at	a	dose	
of	10	mg	to	adults	is	bioequivalent	to	10	mg	hydrocortisone	tablets.9 
The	purpose	of	this	study	was	to	demonstrate	absorption	of	Infacort® 
in	young	children,	and	the	60-	minute	sample	time	was	chosen	as	this	is	
the	approximate	time	for	the	Cmax	after	hydrocortisone	in	children	and	
adults.9,16	There	has	been	no	study	to	date	on	the	pharmacokinetics	
of	hydrocortisone	in	children	under	the	age	of	6	years.	However,	the	
TABLE  2 Summary	of	the	primary	efficacy	analysis	outcomes
Parameter Cohort 1 (n = 12) Cohort 2 (n = 6) Cohort 3 (n = 6) Overall (n = 24)
N	(%)	patients	with	cortisol	levels	significantly	above	baseline	at:
Cmax 12	(100.0)* 6	(100.0)** 6	(100.0)** 24	(100.0)***
60	min 12	(100.0)* 6	(100.0)** 6	(100.0)** 24	(100.0)***
240 min 12	(100.0)* 2	(40.0)a 5	(83.3) 19	(82.6)b,****
Absolute	geometric	mean	±	SD	serum	cortisol	levels	(nmol	L−1)	and	median	(ranges)	at:
Baseline 25.96	±	13.42 
26.19	(14.1,	47.6)
28.00	±	41.84 
16.54	(14.1,	104.5)
14.10	±	0.00c
14.10	(14.1,	14.1)
22.71	±	23.85 
14.10	(14.1,	104.5)
60	min 547.13	±	82.90 
547.96	(424.1,	697.8)
450.10	±	88.93 
432.87	(361.0,	608.3)
815.71	±	473.88 
1037.50	(346.2,	1445.1)
575.77	±	299.53 
535.25	(346.2,	1445.1)
240 min 58.72	±	30.58 
60.65	(31.0,	136.5)
70.74	±	55.28 
57.96	(0.0,	150.1)
55.64	±	194.99 
37.50	(0.0,	504.6)
60.07	±	100.40 
57.96	(0.0,	504.6)
Cmax 547.13	±	82.90 450.10	±	88.93 815.71	±	473.88 575.77	±	299.53
an	=	5,	one	subject	had	no	results	at	240	minutes.
bn	=	23,	one	subject	had	no	results	at	240	minutes.
cBelow	limit	of	quantification	(BLQ)	was	set	to	lower	limit	of	quantification	(LLQ)	for	baseline	samples	and	zero	for	postbaseline	samples.
Significance	of	levels	above	baseline:	*P =	.0005;	**P =	.0313;	***P	<	.0001;	****P =	.0026.
TABLE  3 Responses	to	palatability	questionnaire	among	children	in	Cohort	1
Question No. of responses
No. of events (%)
1 Very good 2 3 Not good/not bad 4 5 Very bad
Q1.	How	did	the	medicine	smell? 6 1	(16.7) 0 4	(66.7) 0 1	(16.7)
Q2.	What	was	it	like	to	swallow	the	medicine 6 3	(50.0) 0 1	(16.7) 0 2	(33.3)
Q3.	What	did	the	medicine	taste	like 6 3	(50.0) 0 3	(50.0) 0 0
Q4.	How	did	the	medicine	feel	in	your	mouth 6 3	(50.0) 0 1	(16.7) 2	(33.3) 0
Q5.	Would	you	take	this	medicine	again? 6 4	(66.7) 0 1	(16.7) 0 1	(16.7)
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mean Cmax	of	Infacort
®	after	dosing	in	these	children	was	626	nmol	L−1,	
very	similar	to	the	reported	Cmax	of	a	standard	10	mg	dose	of	Infacort
® 
and	hydrocortisone	 tablet	 given	 to	 adults	of	566	and	598	nmol	L−1,	
respectively.9	Thus,	it	appears	the	absorption	of	Infacort®	was	similar	
in	very	young	children	to	that	seen	in	adults.
By	 240	minutes	 after	 Infacort,	 cortisol	 concentrations	 for	 all	
three	cohorts	had	dropped	to	<100	nmol	L−1	 in	the	majority	of	chil-
dren,	although	still	above	baseline	in	most	children.	These	results	are	
similar	 to	 those	 found	 in	healthy	dexamethasone-	suppressed	volun-
teers	 given	hydrocortisone	5	mg	where	 the	mean	±	SD	 cortisol	was	
86	±	21	nmol	L−1.9	These	 results	also	 reflect	 the	previous	 reports	of	
cortisol	 levels	during	hydrocortisone	replacement	 in	paediatrics.17 In 
20	children	on	twice	or	thrice	daily	hydrocortisone	replacement	reg-
imens,	children	on	both	regimes	experienced	high	peak	cortisol	con-
centrations	followed	by	periods	of	hypocortisolaemia.	However,	these	
periods	of	hypocortisolaemia	did	not	correlate	with	fatigue	or	reduced	
levels	of	activity.17	In	children	aged	6-	20	years	studied	after	their	stan-
dard	morning	dose	of	hydrocortisone,	the	mean	(range)	time	to	a	corti-
sol	<100	nmol	L−1	was	289	(140-	540)	minutes.16	Variability	in	cortisol	
levels	after	oral	hydrocortisone	administration	has	been	reported	and	
suggested	to	be	due	to	variability	in	clearance	between	patients.16,18 
The	variability	in	cortisol	levels	between	the	cohorts	is	additionally	ex-
plained	by	the	higher	dose	of	hydrocortisone	per	BSA	in	the	neonatal	
group	(cohort	3)	who	in	some	centres	are	dosed	with	a	quarter	of	a	
10	mg	tablet	as	there	 is	no	dose-	appropriate	paediatric	 formulation.	
Further	studies	are	now	needed	to	determine	the	optimum	replace-
ment	regime	in	childhood	using	a	therapy	such	as	Infacort®	which	is	
available	in	a	dose-	appropriate	form	designed	for	children.
Drug	dosing	 in	neonates	 is	 challenging	due	 to	 significant	differ-
ences	 in	 drug	 absorption,	 distribution,	 metabolism	 and	 elimination	
compared	to	older	children	and	adults.	Most	drugs	given	to	neonates	
are	 insufficiently	 studied.19	 Neonates	 are	 extremely	 vulnerable	 to	
medication	 errors.20	Variability	 in	 response	 to	 oral	 dosing	 has	 been	
seen	in	neonates	with	other	oral	medications	such	as	phenobarbital,21 
methadone22	and	digoxin.23
The	palatability	questionnaire	was	a	parent-	reported	measure,	so	
may	not	completely	reflect	the	child’s	experience.	However,	parent-	
reported	outcome	measures	have	been	correlated	with	clinical	out-
comes	 in	some	childhood	 illnesses	and	are	standard	of	care	where	
children	are	unable	to	participate.24	It	was	reassuring	that	in	the	old-
est	children	who	could	complete	the	form,	the	parents’	and	children’s	
perceptions	of	Infacort®	seemed	similar.	Tolerability	of	Infacort® in 
children	under	the	age	of	6	years	was	similar	to	that	of	adults	where	
the	majority	considered	it	either	good	or	neutral.9	This	is	important	
as	 compounded	 hydrocortisone	 is	 often	 mixed	 with	 a	 sweetener,	
following	 methods	 used	 worldwide,	 such	 as	 Ora-	sweet®	 (Perrigo	
Company,	Allegan,	Michigan,	USA),	which	contains	sucrose,	and	so	
could	have	led	to	a	nonsweet	formulation	being	poorly	received.25,26 
Sweetening	of	paediatric	 formulations	 in	 this	way,	 to	 improve	pal-
atability,	 goes	 against	 current	 recommendations	 for	 developing	 li-
censed	products	and	raises	concerns	about	accidental	ingestion	and	
poisoning	in	children	(Guideline	on	pharmaceutical	development	of	
medicines	for	paediatric	use	EMA/CHMP/QWP/805880/2012	Rev.	
2).	The	palatability	questionnaire	was	answered	after	the	first	expo-
sure	 to	 Infacort®	 and	during	 the	 study	visit;	 therefore,	 it	does	not	
reflect	continuous	daily	experience	with	the	drug.
This	 study	 highlights	 the	 challenges	 in	 developing	 medications	
for	neonates,	infants	and	children	and	demonstrates	that	with	careful	
consideration	these	can	be	overcome.	To	address	concerns	regarding	
testing	 in	 neonates,	we	 used	 three	 cohorts	 of	 descending	 age	 only	
progressing	to	test	neonates	in	Cohort	3	after	safety	had	been	estab-
lished	 in	 the	older	cohorts	and	safety	confirmed	by	an	 Independent	
TABLE  4 Summary	of	TEAEs	and	by	system	organ	class	and	preferred	term
Safety parameter Cohort 1 (n = 12) Cohort 2 (n = 6) Cohort 3 (n = 6) Overall (n = 24)
No.	of	events/subjects	(%	of	subjects	in	cohort)
TEAEs 7/4	(33) 2/2	(33) 3/2	(33) 12/8	(33)
Serious	TEAEs 0 0 0 0
TEAE	intensity
Mild 5/3	(25) 2/2	(33) 3/2	(33) 10/7	(29)
Moderate 2/1	(8) 0 0 2/1	(4)
Severe 0 0 0 0
Gastrointestinal	disorder 3/3	(25) 1/1	(17) 3/2	(33) 7/6	(25)
Diarrhoea 2/2	(17) 1/1	(17) 0 3/3	(13)
Vomiting 1/1	(8) 0 1/1	(17) 2/2	(8)
Spitting	up 0 0 2/1	(17) 2/1	(4)
Skin	and	subcutaneous	disorders 3/2	(17) 1/1	(17) 0 2/2	(8)
Rash 1/1	(8) 0 0 2/1	(4)
Hyperhidrosis 2/1	(8) 0 0 1/1	(4)
General	disorders	and	administration	site	conditions
Fatigue 1/1	(8) 0 0 1/1	(4)
TEAE,	treatment-	emergent	adverse	event.
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Data	Monitoring	Committee.	Recruiting	neonates	to	a	clinical	trial	is	a	
major	challenge	as	recruitment,	consent	and	the	study	needed	to	be	
completed	within	the	first	28	days	of	life.	To	address	this,	we	agreed	
with	the	ethics	committee	that	there	would	be	a	single	centre	and	that	
the	team	would	travel	(“fly”)	to	any	site	where	a	neonate	with	AI/CAH	
was	born	and	administer	the	trial	as	from	the	single	site.	Germany	has	
a	well-	established	neonatal	screening	programme	with	the	advantage	
that	 clinicians	 identified	 neonates	 shortly	 after	 birth.	This	 approach	
was	successful,	and	5	of	the	6	neonates	were	recruited	from	sites	out-
side	of	the	central	site.
Limitations	in	this	study	include	the	small	number	of	subjects	and	
the	number	of	samples.	However,	the	investigators	and	ethics	commit-
tee	were	keen	that	the	study	should	be	undertaken	as	close	to	routine	
standard	of	care	as	possible,	and	not	include	excess	samplings.	As	all	
children	born	with	AI	are	reviewed	frequently	with	blood	sampling	it	
was	possible	to	avoid	extra	visits	and	extra	cannulation.	The	palatabil-
ity	questionnaire	was	given	to	every	parent/carer	and	to	every	child	
over	3	years	of	age.	The	questionnaire	was	not	completed	in	5	of	12	
children	of	the	first	cohort	as	they	were	<3	years	and/or	would	not	be	
expected	to	understand	the	questionnaire.	Assessment	of	palatability	
in	the	very	young	is	challenging	but	could	be	undertaken	in	older	chil-
dren	in	future	studies.
5  | CONCLUSIONS
The	novel,	paediatric,	multiparticulate	granule	formulation,	Infacort®,	
is	 well	 tolerated,	 easy	 to	 administer	 to	 neonates,	 infants	 and	 chil-
dren,	and	shows	good	absorption,	with	cortisol	 levels	at	60	minutes	
after	administration	similar	to	physiological	cortisol	 levels	 in	healthy	
children.	 Cortisol	 levels	 >150	nmol	L−1	were	 achieved	 at	 Cmax in all 
subjects,	and	the	mean	cortisol	level	was	580	nmol	L−1	for	the	over-
all	population.	Importantly,	no	safety	concerns	were	reported	in	this	
study,	and	Infacort®	was	easy	to	dose	and	palatable	according	to	both	
subjects	and	parents/carers.
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